Publication
Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugDovitinibcivic_curation1.00
- geneFGF3civic_curation1.00
- geneFGFR1civic_curation1.00
- geneFGFR2civic_curation1.00
- variantFGF3 Amplificationcivic_curation1.00
- variantFGFR1 Amplificationcivic_curation1.00
- variantFGFR2 Amplificationcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23658459
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FGF3 Amplification1 | ||||||||
| Dovitinib | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID160681 patients were enrolled in a clinical trial with the FGFR inhibitor dovitinib. Four of these patients had FGF3 amplifications (qPCR) and showed tumor reductions of 100%, 30.8%, 23.0%, and 7.5%, resp… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC | civic |
| FGFR1 Amplification1 | ||||||||
| Dovitinib | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1604Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC | civic |
| FGFR2 Amplification1 | ||||||||
| Dovitinib | Malignant Breast Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID1605Dovitinib was evaluated in-vitro, in xenograft and in a phase 2 study. Dovitinib inhibited proliferation in one FGFR1- and one FGFR2-amplified breast cancer cell lines at higher IC50 values than in 11… (full text at CIViC) PMID 23658459 · André et al., 2013 · Open in CIViC | civic |